浙江京新药业股份有限公司 独立董事提名人声明与承诺 提名人浙江京新药业股份有限公司第八届董事会现就提名 雷英为浙江京新药业股份有限公司第九届董事会独立董事候选 人发表公开声明。被提名人已书面同意出任浙江京新药业股份 有限公司第九届董事会独立董事候选人（参见该独立董事候选 人声明）。本次提名是在充分了解被提名人职业、学历、职称、 详细的工作经历、全部兼职、有无重大失信等不良记录等情况 后作出的，本提名人认为被提名人符合相关法律、行政法规、 部门规章、规范性文件和深圳证券交易所业务规则对独立董事 候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过浙江京新药业股份有限公司第八届 董事会提名委员会或者独立董事专门会议资格审查，提名人与 被提名人不存在利害关系或者其他可能影响独立履职情形的密 切关系。 √是 □ 否 如否，请详细说明：____________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七 十八条等规定不得担任公司董事的情形。 √是 □ 否 如否，请详细说明：____________________________ 三、被提名人符合中国证监会 ...

浙江京新药业股份有限公司 独立董事提名人声明与承诺 提名人浙江京新药业股份有限公司第八届董事会现就提名 黄韬为浙江京新药业股份有限公司第九届董事会独立董事候选 人发表公开声明。被提名人已书面同意出任浙江京新药业股份 有限公司第九届董事会独立董事候选人（参见该独立董事候选 人声明）。本次提名是在充分了解被提名人职业、学历、职称、 详细的工作经历、全部兼职、有无重大失信等不良记录等情况 后作出的，本提名人认为被提名人符合相关法律、行政法规、 部门规章、规范性文件和深圳证券交易所业务规则对独立董事 候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过浙江京新药业股份有限公司第八届 董事会提名委员会或者独立董事专门会议资格审查，提名人与 被提名人不存在利害关系或者其他可能影响独立履职情形的密 切关系。 √是 □ 否 如否，请详细说明：____________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七 十八条等规定不得担任公司董事的情形。 √是 □ 否 如否，请详细说明：____________________________ 三、被提名人符合中国证监会 ...

证券代码：002020 证券简称：京新药业 公告编号：2025049 浙江京新药业股份有限公司 4、会议召开的日期、时间： 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证公告的内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 经浙江京新药业股份有限公司（以下简称"公司"）第八届董事会第十七次会 议审议通过了《关于提请召开 2025 年第一次临时股东大会的议案》，公司将于 2025 年 10 月 10 日（星期五）召开 2025 年第一次临时股东大会。具体事项如下： 一、召开会议的基本情况 1、会议届次：浙江京新药业股份有限公司 2025 年第一次临时股东大会。 2、会议召集人：浙江京新药业股份有限公司董事会。 3、会议召开的合法、合规性：经公司第八届董事会第十七次会议审议同意 召开 2025 年第一次临时股东大会，其召集程序符合《公司法》等有关法律法规、 部门规章、规范性文件和《公司章程》的规定。 现场会议时间：2025 年 10 月 10 日 9:30 起。 网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 10 月 10 日 9:15—9 ...

证券代码：002020 证券简称：京新药业 公告编号：2025046 浙江京新药业股份有限公司 第八届监事会第十四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江京新药业股份有限公司（以下简称"公司"）第八届监事会第十四次会 议通知于 2025 年 9 月 12 日以电子邮件形式发出，会议于 2025 年 9 月 24 日在公 司 201 会议室召开。会议应到监事 3 名，实到 3 名，会议召开符合《公司法》和 《公司章程》的有关规定。会议由监事会主席胡天庆先生主持，会议审核并一致 通过了如下决议： 1、以 3 票同意、0 票反对和 0 票弃权的表决结果，审核通过了《关于修订< 公司章程>的议案》。 根据《公司法》相关规定，结合公司实际情况，公司将不再设置监事会，监 事会的职权由董事会审计委员会行使，《监事会议事规则》等监事会相关制度相 应废止，同时《公司章程》中相关条款亦作出相应修订。本议案尚需提交公司 2025 年第一次临时股东大会审议。 公司监事会取消后，胡天庆先生不再担任公司监事会主席，徐小军先生、林 芬娟女士不再担任公司监事。截至本公 ...

第八届董事会第十七次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江京新药业股份有限公司（以下简称"公司"）第八届董事会第十七次会 议通知于 2025 年 9 月 12 日以电子邮件形式发出，会议于 2025 年 9 月 24 日在公 司 201 会议室召开。会议应到董事 9 名，实到董事 8 名，独立董事徐攀女士出差 在外委托独立董事雷英女士代为出席，公司监事及高级管理人员列席了会议，会 议召开符合《公司法》及《公司章程》的有关规定。会议由公司董事长吕钢先生 主持，会议经表决形成如下决议： 证券代码：002020 证券简称：京新药业 公告编号：2025045 浙江京新药业股份有限公司 公司第八届董事会任期即将届满，按照《公司法》《公司章程》等有关规定， 公司董事会需进行换届选举。经公司第八届董事会推荐，董事会提名委员会任职 资格审查，同意提名吕钢先生、王能能先生、洪贇飞先生、吕佳琦女士和李必祥 先生为第九届董事会非独立董事候选人；同意提名雷英女士、徐攀女士和黄韬先 生为第九届董事会独立董事候选人。 上述《股东会议事规则》《董事会议事规则》《独立 ...

证券之星消息，9月24日化学制药板块较上一交易日上涨0.13%，向日葵领涨。当日上证指数报收于 3853.64，上涨0.83%。深证成指报收于13356.14，上涨1.8%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 8.57 | 20.03% | 300.34万 | | 24.00亿 | | 002020 | 京新药业 | 21.63 | 10.02% | 27.78万 | | 5.81亿 | | 002294 | 信立泰 | 60.24 | 10.01% | 14.80万 | | 8.69% | | 300584 | 海辰药业 | 61.56 | 7.98% | 15.43万 | | 9.31亿 | | 688197 | 首药控股 | 48.28 | 6.93% | 3.02万 | | 1.41亿 | | 688302 | 海创药业 | 55.69 | 6.62% | 4.06万 | | 2.26亿 | | 00 ...

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The pricing power of innovative drugs is improving, reflecting the global competitiveness of Chinese pharmaceutical companies [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions due to continued domestic substitution and accelerated overseas business progress [2]. - The neurosurgery and neurointervention fields are experiencing stable growth post-collection, with new products being launched [2]. - The high-value consumables market is expected to benefit from ongoing domestic replacement and the introduction of new products [2]. Group 3: Medical Devices - The medical device sector is seeing a recovery in bidding prices, with ongoing high-speed growth in bidding data this year [2]. - Companies are entering a phase of inventory reduction, with performance expected to improve in the second half of the year [2]. - The low-value consumables sector is experiencing product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is concentrating on central state-owned enterprises, gradually clearing the competitive landscape [2]. - The demand side is expected to see continuous upgrades to new products, with industry sentiment gradually improving [2]. Group 5: API (Active Pharmaceutical Ingredients) - The API sector is benefiting from the end of a capital expenditure peak, with three growth logic points driving upward trends: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies in the API sector are expected to see explosive growth in revenue and profits [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is witnessing a recovery in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs and ongoing observation of collection progress [2]. - The retail pharmacy sector is influenced by the pace of supply-side clearing and business model upgrades, with expectations of increased store closures in the second half of 2025 [2]. Group 8: Research and Development Services - The domestic innovative drug business development is heating up, likely driving downstream demand recovery [2]. - The overseas market presents significant growth opportunities for domestic companies, leveraging cost-effectiveness and service differentiation [2].

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The industry is positioned for a "Davis double" effect, where both performance and valuation are expected to improve [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions, while domestic replacements continue to grow, and overseas business progresses rapidly [2]. - The neurosurgery and neurointervention fields are stabilizing after centralized procurement, with new products expected to contribute to growth [2]. Group 3: Medical Devices - The medical device sector is experiencing a high-speed growth in bidding data, with companies entering a destocking phase, which is expected to improve performance in the second half of the year [2]. - The low-value consumables sector is seeing continuous product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is increasingly concentrated among state-owned enterprises, leading to a clearer competitive landscape [2]. - The demand side is expected to upgrade towards new products, gradually improving the industry's overall health [2]. Group 5: API (Active Pharmaceutical Ingredients) - The industry is at an upward turning point due to the end of a capital expenditure peak, combined with three growth drivers: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies are expected to see explosive growth in revenue and profits in the medium term [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is seeing a revival in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs, while the retail pharmacy sector is influenced by supply-side adjustments and business model upgrades [2]. - The performance of offline pharmacies is expected to improve in the second half of 2025, with leading chains like YaoXingTang making progress in store upgrades [2]. Group 8: Research Reports - A series of in-depth research reports on various companies and sectors within the pharmaceutical and medical device industries have been published, highlighting their growth potential and market positioning [3][4].

Summary of Jinxin Pharmaceutical Conference Call Company Overview - **Company**: Jinxin Pharmaceutical - **Industry**: Pharmaceutical Key Points Business Performance - Jinxin Pharmaceutical's finished drug business has shown continuous improvement in hospital, outpatient, and formulation export sectors, providing a solid performance guarantee for the company [2][3] - Profit is expected to achieve double-digit growth in 2025, with growth rates exceeding double digits in 2026 and beyond [2][3] - The pressure from accelerated depreciation is expected to decrease significantly after 2025, releasing approximately 100 million RMB in profit [2][3] - The main business profit is projected to reach 800 million RMB in 2025, leading to a potential company valuation of 12 billion RMB based on a 15x price-to-earnings ratio [2][3] Innovation Drug Commercialization - Significant progress has been made in the commercialization of innovative drugs, with the peak sales expectation for Tidasini raised from 1 billion RMB to 1.5 billion RMB [2][4] - The peak sales expectation for Kailaqin has also been increased from 500 million RMB to 1.5 billion RMB, providing substantial valuation flexibility for the company [2][4] Early Research and Development Focus - Jinxin Pharmaceutical is focusing on early-stage research in the cardiovascular and central nervous system (CNS) fields [2][5] - The company is developing LPA small molecule inhibitors, which have gained attention following Eli Lilly's successful Phase II clinical trial at the end of 2024 [2][5] - Other pharmaceutical companies, such as CSPC and Hengrui Medicine, have engaged in significant business development (BD) transactions related to LPA small molecule inhibitors, indicating the market's potential [2][5] - Pfizer is currently in concentrated BD negotiations with Jinxin regarding LPA small molecule inhibitors, which could lead to significant valuation flexibility if successful [2][5] Market Potential - The market potential for LPA small molecule inhibitors is highlighted by the substantial upfront payments and total licensing fees offered by major pharmaceutical companies [2][5] - Continuous monitoring of clinical progress and subsequent BD transactions is essential for assessing future opportunities [2][5]

Core Viewpoint - The company is currently in the clinical I phase for its LP(a) lowering drug, and the external licensing work is progressing, with updates to be provided through official announcements [1] Group 1 - An investor inquired about the progress of the company's LP(a) lowering drug BD business, expressing concerns about the perceived slow efficiency [1] - The company confirmed that the LP(a) lowering drug is in the clinical I phase and that the external licensing efforts are ongoing [1]